Keros Therapeutics, Inc. $KROS Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd cut its stake in Keros Therapeutics, Inc. (NASDAQ:KROS) by 53.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 48,545 shares of the company’s stock after selling 56,333 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Keros Therapeutics were worth $768,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Canada Pension Plan Investment Board acquired a new stake in shares of Keros Therapeutics in the 2nd quarter worth approximately $4,251,000. Caption Management LLC boosted its position in Keros Therapeutics by 114.1% during the second quarter. Caption Management LLC now owns 36,078 shares of the company’s stock worth $482,000 after purchasing an additional 291,997 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Keros Therapeutics by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after purchasing an additional 205,022 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in Keros Therapeutics by 154.2% in the third quarter. Assenagon Asset Management S.A. now owns 257,518 shares of the company’s stock valued at $4,074,000 after purchasing an additional 156,221 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Keros Therapeutics by 89.9% in the second quarter. Bank of America Corp DE now owns 295,477 shares of the company’s stock valued at $3,945,000 after buying an additional 139,865 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS opened at $18.40 on Tuesday. The firm has a market cap of $560.57 million, a P/E ratio of 11.95 and a beta of 0.89. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $22.55. The firm’s 50 day moving average price is $19.52 and its 200 day moving average price is $16.81.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.93. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.The company had revenue of $14.26 million for the quarter, compared to analyst estimates of $4.22 million. During the same quarter in the prior year, the company posted ($1.41) EPS. The business’s revenue for the quarter was up 3585.6% compared to the same quarter last year. As a group, equities analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Zacks Research cut shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Wedbush upped their price target on shares of Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a research report on Monday, December 29th. Oppenheimer restated an “outperform” rating and set a $27.00 price objective (up from $23.00) on shares of Keros Therapeutics in a research report on Wednesday, November 12th. Finally, TD Cowen raised Keros Therapeutics to a “hold” rating in a research note on Friday, December 19th. Five investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $22.29.

Keros Therapeutics Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.